Author Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 11:12:40 ON 02 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Jan 2008  VOL 148 ISS 1
FILE LAST UPDATED: 1 Jan 2008  (20080101/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D QUE L25
L12           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SULPHASALAZINE/CN
L17        1760 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12
L19        9804 SEA FILE=HCAPLUS ABB=ON  PLU=ON  INTESTINE, DISEASE+OLD,NT/CT
                (L) INFLAMMAT?/OBI
L20         216 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 AND L19
L21         140 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L20 AND (PRY<=2003 OR
                AY<=2003 OR PY<=2003)
L23         128 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L21 AND 1/SC,SX
L24          15 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HORIZOE T?/AU
L25           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L24 AND L23


=> FILE TOXCENTER
FILE 'TOXCENTER' ENTERED AT 11:12:52 ON 02 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


FILE COVERS 1907 TO 24 Dec 2007 (20071224/ED)

The MEDLINE file segment has been updated with the National Library of
Medicine's revised 2008 MeSH terms.  See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance
identification.

The BIOSIS segment of TOXCENTER has been augmented with 13,000 records
from 1946 through 1968.

=> D QUE L32
L8            5 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
```

```
                -METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPA
                NOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)
                -A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS
                )-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPH
                ENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL
                ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-
                CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY
                )-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, (AS)-"/CN)
L9           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                -METHYLETHOXY)-, (AS)-"/CN
L10          2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)
L11          1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                -METHYLETHOXY)-, (AS)-"/CN
L24         15 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HORIZOE T?/AU
L27          9 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L8 OR L9 OR L10 OR L11)
L28          2 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L9 OR L11)
L29          1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L28
L30          1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L27
L32          0 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L24 AND (L29 OR L30)


=> FILE USPATFULL
FILE 'USPATFULL' ENTERED AT 11:13:05 ON 02 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Jan 2008 (20080101/PD)
FILE LAST UPDATED: 1 Jan 2008 (20080101/ED)
HIGHEST GRANTED PATENT NUMBER: US7316033
HIGHEST APPLICATION PUBLICATION NUMBER: US2007300346
CA INDEXING IS CURRENT THROUGH 1 Jan 2008 (20080101/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Jan 2008 (20080101/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2007
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2007


=> D QUE L36
L8           5 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                -METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPA
                NOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)
                -A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS
                )-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPH
                ENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL
                ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-
                CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY
                )-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, (AS)-"/CN)
```

```
L9              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, (AS)-"/CN
L10             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)
L11             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, (AS)-"/CN
L27             9 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L8 OR L9 OR L10 OR L11)
L28             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L9 OR L11)
L34             3 SEA FILE=USPATFULL ABB=ON  PLU=ON  (L28 OR L27)
L35             4 SEA FILE=USPATFULL ABB=ON  PLU=ON  HORIZOE T?/AU
L36             1 SEA FILE=USPATFULL ABB=ON  PLU=ON  L35 AND L34


=> DUP REM L25 L32 L36
L32 HAS NO ANSWERS
FILE 'HCAPLUS' ENTERED AT 11:13:31 ON 02 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:13:31 ON 02 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L25
PROCESSING COMPLETED FOR L32
PROCESSING COMPLETED FOR L36
L37             2 DUP REM L25 L32 L36 (0 DUPLICATES REMOVED)
                  ANSWER '1' FROM FILE HCAPLUS
                  ANSWER '2' FROM FILE USPATFULL

=> D IBIB ED ABS HITSTR 1 L37; D IBIB ABS HITSTR L37 2

L37  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:799479  HCAPLUS  Full-text
DOCUMENT NUMBER:          141:289040
TITLE:                    Concomitant drug as therapeutic agent for inflammatory
                          bowel disease
INVENTOR(S):              Horizoe, Tatsuo
PATENT ASSIGNEE(S):       Eisai Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 51 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

    PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
    ----------------      ----   --------    --------------------     --------
    WO 2004082715          A1    20040930    WO 2004-JP3662           20040318 <--
    WO 2004082715          A8    20050512
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
```

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1607103 A1 20051221 EP 2004-721714 20040318 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

US 2006177444 A1 20060810 US 2005-549321 20050916 <--

PRIORITY APPLN. INFO.: JP 2003-77467 A 20030320 <--
WO 2004-JP3662 W 20040318

ED Entered STN: 30 Sep 2004

AB Disclosed is a drug having enhanced efficacy against inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. In particular, disclosed is a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammation inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonist activity. In the application of this therapeutic agent for inflammatory bowel diseases, compound (a) and compound (b) can be administered simultaneously, sep. or with intervals. Thus, a compound 3-[3-[(3-trifluoromethoxybenzyloxycarbonyaminio)methyl]phenyl]-2(S)-isopropoxypropanoic acid (3 mg/kg/day) and sulphasalazine (100 mg/kg/day) were administered to inflammatory bowel disease model mice to examine the effect of the combination.

IT 599-79-1, Sulphasalazine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(concomitant drugs consisting of antiinflammatory agents and PPARγ agonists as therapeutic agents for inflammatory bowel disease)

RN 599-79-1 HCAPLUS

CN Benzoic acid, 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 2 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2006:208450 USPATFULL Full-text
TITLE: Concomitant drug as therapeutic agent for inflammatory bowel disease
INVENTOR(S): **Horizoe, Tatsuo**, Ibaraki, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006177444	A1	20060810	
APPLICATION INFO.:	US 2004-549321	A1	20040318	(10)
	WO 2004-JP3662		20040318	
			20050916	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-77467	20030320

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 1196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonistic activity, wherein the agent is so configured that the compound (a) and the compound (b) are used simultaneously, separately or every scheduled time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **478926-39-5 478926-45-3**
(concomitant drugs consisting of antiinflammatory agents and PPARγ agonists as therapeutic agents for inflammatory bowel disease)
RN 478926-39-5 USPATFULL
CN Benzenepropanoic acid, 3-[(2R)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 478926-45-3 USPATFULL
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



Search History

L1 1 SEA ABB=ON PLU=ON US2005-549321/APPS

FILE 'REGISTRY' ENTERED AT 08:45:35 ON 02 JAN 2008

L2 66 SEA ABB=ON PLU=ON (100986-85-4/BI OR 104987-11-3/BI OR 111025-46-8/BI OR 15722-48-2/BI OR 161600-01-7/BI OR 170277-31-3/BI OR 185243-69-0/BI OR 213252-19-8/BI OR 251565-85-2/BI OR 25953-19-9/BI OR 32986-56-4/BI OR 331731-18-1/BI OR 331741-94-7/BI OR 334010-93-4/BI OR 334010-94-5/BI OR 334011-75-5/BI OR 336128-48-4/BI OR 378-44-9/BI OR 428863-50-7/BI OR 443-48-1/BI OR 446-86-6/BI OR 467236-05-1/BI OR 467236-11-9/BI OR 470668-07-6/BI OR 470668-33-8/BI OR 478923-80-7/BI OR 478925-95-0/BI OR 478926-13-5/BI OR 478926-16-8/BI OR 478926-30-6/BI OR 478926-36-2/BI OR 478926-37-3/BI OR 478926-39-5/BI OR 478926-42-0/BI OR 478926-43-1/BI OR 478926-45-3/BI OR 478926-48-6/BI OR 478926-49-7/BI OR 478926-51-1/BI OR 478926-60-2/BI OR 478926-87-3/BI OR 478926-92-0/BI OR 478927-11-6/BI OR 478927-20-7/BI OR 478929-06-5/BI OR 478929-12-3/BI OR 499788-20-4/BI OR 50-04-4/BI OR 50-23-7/BI OR 50-24-8/BI OR 50-44-2/BI OR 51333-22-3/BI OR 53-03-2/BI OR 560131-16-0/BI OR 59-05-2/BI OR 599-79-1/BI OR 60189-34-6/BI OR 69-53-4/BI OR 765300-31-0/BI OR 79217-60-0/BI OR 80573-04-2/BI OR 81103-11-9/BI OR 82419-36-1/BI OR 83-43-2/BI OR 89-57-6/BI OR 93107-08-5/BI)

L3 7 SEA ABB=ON PLU=ON L2 AND CL/ELS AND F/ELS

L5 5 SEA ABB=ON PLU=ON L3 NOT DICHLORO?/CNS

L6 4 SEA ABB=ON PLU=ON L5 NOT QUINOLINECARBOXYLIC ACID?/CNS

D SCAN

L7 2 SEA ABB=ON PLU=ON L6 AND CYANOPHENOXY?/CNS

D SCAN

E "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2

L8 5 SEA ABB=ON PLU=ON ("BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(1-METHYLETHOXY)-, (AS)-"/CN)

L9 1 SEA ABB=ON PLU=ON "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, (AS)-"/CN

E "BENZENEPROPANOIC ACID, 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2

L10 2 SEA ABB=ON PLU=ON ("BENZENEPROPANOIC ACID, 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)

L11 1 SEA ABB=ON PLU=ON "BENZENEPROPANOIC ACID, 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, (AS)-"/CN

L12 1 SEA ABB=ON PLU=ON SULPHASALAZINE/CN

```
     FILE 'HCAPLUS' ENTERED AT 08:58:03 ON 02 JAN 2008
L13           3 SEA ABB=ON  PLU=ON  L9
L14           2 SEA ABB=ON  PLU=ON  L8
L15           2 SEA ABB=ON  PLU=ON  L11
L16           2 SEA ABB=ON  PLU=ON  L10
L17        1760 SEA ABB=ON  PLU=ON  L12
L18           3 SEA ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L19        9804 SEA ABB=ON  PLU=ON  INTESTINE, DISEASE+OLD,NT/CT (L) INFLAMMAT?
                 /OBI
L20         216 SEA ABB=ON  PLU=ON  L17 AND L19
L21         140 SEA ABB=ON  PLU=ON  L20 AND (PRY<=2003 OR AY<=2003 OR PY<=2003)
L22           0 SEA ABB=ON  PLU=ON  L12(L)L19
L23         128 SEA ABB=ON  PLU=ON  L21 AND 1/SC,SX
L24          15 SEA ABB=ON  PLU=ON  HORIZOE T?/AU
L25           1 SEA ABB=ON  PLU=ON  L24 AND L23

     FILE 'HCAPLUS' ENTERED AT 09:44:49 ON 02 JAN 2008
L26           1 SEA ABB=ON  PLU=ON  L17 AND L18

     FILE 'REGISTRY' ENTERED AT 10:40:54 ON 02 JAN 2008
L27           9 SEA ABB=ON  PLU=ON  (L8 OR L9 OR L10 OR L11)

     FILE 'REGISTRY' ENTERED AT 10:42:29 ON 02 JAN 2008
L28           2 SEA ABB=ON  PLU=ON  (L9 OR L11)

     FILE 'TOXCENTER' ENTERED AT 11:06:21 ON 02 JAN 2008
L29           1 SEA ABB=ON  PLU=ON  L28
L30           1 SEA ABB=ON  PLU=ON  L27
L32           0 SEA ABB=ON  PLU=ON  L24 AND (L29 OR L30)
L33           1 SEA ABB=ON  PLU=ON  (L29 OR L30)

     FILE 'USPATFULL' ENTERED AT 11:08:41 ON 02 JAN 2008
L34           3 SEA ABB=ON  PLU=ON  (L28 OR L27)
L35           4 SEA ABB=ON  PLU=ON  HORIZOE T?/AU
L36           1 SEA ABB=ON  PLU=ON  L35 AND L34

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 11:13:31 ON 02 JAN 2008
L37           2 DUP REM L25 L32 L36 (0 DUPLICATES REMOVED)


     FILE 'HCAPLUS' ENTERED AT 11:14:28 ON 02 JAN 2008
L38           2 SEA ABB=ON  PLU=ON  (L26 OR L18) NOT L25

     FILE 'TOXCENTER' ENTERED AT 11:14:57 ON 02 JAN 2008
               D QUE L33
L39           1 SEA ABB=ON  PLU=ON  L33 NOT L32

     FILE 'USPATFULL' ENTERED AT 11:15:16 ON 02 JAN 2008
               D QUE L34
L40           2 SEA ABB=ON  PLU=ON  L34 NOT L36

     FILE 'TOXCENTER, HCAPLUS, USPATFULL' ENTERED AT 11:15:44 ON 02 JAN 2008
L41           4 DUP REM L39 L38 L40 (1 DUPLICATE REMOVED)
```

Text Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 11:14:28 ON 02 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Jan 2008  VOL 148 ISS 1
FILE LAST UPDATED: 1 Jan 2008  (20080101/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D QUE L26
L8             5 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                 -METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPA
                 NOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)
                 -A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS
                 )-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPH
                 ENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL
                 ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-
                 CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY
                 )-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                 1-METHYLETHOXY)-, (AS)-"/CN)
L9             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                 -METHYLETHOXY)-, (AS)-"/CN
L10            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                 1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                 1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)
L11            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                 3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                 -METHYLETHOXY)-, (AS)-"/CN
L12            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SULPHASALAZINE/CN
L13            3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9
L14            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L8
L15            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11
```

```
L16             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L10
L17          1760 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12
L18             3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L26             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 AND L18


=> D QUE L18
L8              5 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPA
                  NOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)
                  -A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS
                  )-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPH
                  ENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL
                  ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-
                  CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY
                  )-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, (AS)-"/CN)
L9              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, (AS)-"/CN
L10             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)
L11             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, (AS)-"/CN
L13             3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9
L14             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L8
L15             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11
L16             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L10
L18             3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)


=> S L26,L18 NOT L25
L38             2 (L26 OR L18) NOT L25

=> FILE TOXCENTER
FILE 'TOXCENTER' ENTERED AT 11:14:57 ON 02 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


FILE COVERS 1907 TO 24 Dec 2007 (20071224/ED)

The MEDLINE file segment has been updated with the National Library of
Medicine's revised 2008 MeSH terms.  See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance
identification.

The BIOSIS segment of TOXCENTER has been augmented with 13,000 records
from 1946 through 1968.

=> D QUE L33
```

```
L8              5 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPA
                  NOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)
                  -A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS
                  )-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPH
                  ENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL
                  ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-
                  CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY
                  )-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, (AS)-"/CN)
L9              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, (AS)-"/CN
L10             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                  1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)
L11             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                  3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, (AS)-"/CN
L27             9 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L8 OR L9 OR L10 OR L11)
L28             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L9 OR L11)
L29             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L28
L30             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L27
L33             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  (L29 OR L30)


=> S L33 NOT L32
L39           1 L33 NOT L32

=> FILE USPATFULL
FILE 'USPATFULL' ENTERED AT 11:15:16 ON 02 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Jan 2008 (20080101/PD)
FILE LAST UPDATED: 1 Jan 2008 (20080101/ED)
HIGHEST GRANTED PATENT NUMBER: US7316033
HIGHEST APPLICATION PUBLICATION NUMBER: US2007300346
CA INDEXING IS CURRENT THROUGH 1 Jan 2008 (20080101/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Jan 2008 (20080101/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2007
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2007


=> D QUE L34
L8              5 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                  3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                  -METHYLETHOXY)-, CALCIUM SALT, (AS)-"/CN OR "BENZENEPROPA
                  NOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)
                  -A-(1-METHYLETHOXY)-, CALCIUM SALT, TRIHYDRATE, (AS
                  )-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-CHLORO-2-CYANOPH
                  ENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY)-, ETHYL
                  ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID, 3-((2S)-3-(4-
```

```
                CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1-METHYLETHOXY
                )-, METHYL ESTER, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, (AS)-"/CN)
L9              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                3-((2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                -METHYLETHOXY)-, (AS)-"/CN
L10             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("BENZENEPROPANOIC ACID,
                3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, (AS)-"/CN OR "BENZENEPROPANOIC ACID,
                3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-HYDROXYPROPOXY)-A-(
                1-METHYLETHOXY)-, ETHYL ESTER, (AS)-"/CN)
L11             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANOIC ACID,
                3-((2R)-3-(4-CHLORO-2-CYANOPHENOXY)-2-FLUOROPROPOXY)-A-(1
                -METHYLETHOXY)-, (AS)-"/CN
L27             9 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L8 OR L9 OR L10 OR L11)
L28             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L9 OR L11)
L34             3 SEA FILE=USPATFULL ABB=ON  PLU=ON  (L28 OR L27)


=> S L34 NOT L36
L40           2 L34 NOT L36

=> DUP REM L39 L38 L40
FILE 'TOXCENTER' ENTERED AT 11:15:44 ON 02 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 11:15:44 ON 02 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:15:44 ON 02 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L39
PROCESSING COMPLETED FOR L38
PROCESSING COMPLETED FOR L40
L41             4 DUP REM L39 L38 L40 (1 DUPLICATE REMOVED)
                  ANSWER '1' FROM FILE TOXCENTER
                  ANSWER '2' FROM FILE HCAPLUS
                  ANSWERS '3-4' FROM FILE USPATFULL

=> D IALL L41 1

L41  ANSWER 1 OF 4  TOXCENTER COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER:     2003:9513  TOXCENTER  Full-text
COPYRIGHT:            Copyright 2008 ACS
DOCUMENT NUMBER:      CA13804039105F
TITLE:                Preparation of phenylpropionic acid and indolylpropionic
                      acid derivatives and salt thereof as dual or triple
                      agonists of peroxisome proliferator-activated receptors
                      (PPAR)
AUTHOR(S):            Matsuura, Fumiyoshi; Emori, Eita; Shinoda, Masanobu;
                      Clark, Richard; Kasai, Shunji; Yoshitomi, Hideki;
                      Yamazaki, Kazuto; Inoue, Takashi; Miyashita, Sadakazu; et
                      al.
CORPORATE SOURCE:     ASSIGNEE: Eisai Co., Ltd.
PATENT INFORMATION:   WO 2002100812 A1 19 Dec 2002
```

SOURCE: (2002) PCT Int. Appl., 404 pp.
CODEN: PIXXD2.
COUNTRY: JAPAN
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2002:964312
LANGUAGE: Japanese
ENTRY DATE: Entered STN: 13 Jan 2003
Last Updated on STN: 2 May 2006

ABSTRACT:
Carboxylic acid derivs. represented by general formula (I), salts or esters thereof, or hydrates thereof [wherein R1 = H, HO, halo, CO2H, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, C1-6 hydroxyalkylthio, C1-6 aminoalkyl, C1-6 aminoalkoxy, C1-6 aminoalkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 haloalkylthio, C2-12 alkoxyalkyl, C2-12 alkoxyalkoxy, C2-12 alkoxyalkylthio, C3-7 cycloalkyl, C3-7 cycloalkoxy, etc.; L, M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = CO2H; a solid line accompanied by a dotted line represents a single or double bond; X = a single bond, O, N-(un)substituted NHCQ1O, OCQ1NH, CQ1NHO, ONHCQ1, Q2SO2, SO2Q2, etc., wherein [Q1 = O, S; Q2 = O, (un)substituted NH]; Y = 5 to 14-membered aromatic group or C3-7 alicyclic hydrocarbon group optionally having ≥1 heteroatoms and ≥1 substituents; the ring Z = 5 to 14-membered aromatic group optionally having 1-4 substituents and ≥1 heteroatoms wherein a part of the ring is optionally saturated] are prepared These compds. are dual agonists of PPAR α and γ and triple agonists of PPAR α, β(δ), and γ and are useful as ameliorants (improvers) of insulin resistance, hypolipidemics, anti-osteoporosis agents, antiinflammatory agents, immunomodulators, and anticancer agents, and preventives and/or remedies for diabetes, diabetes complications, fragile X syndrome, hyperlipidemia, obesity, and digestive tract (gastrointestinal) diseases. The gastrointestinal diseases include (1) gastrointestinal inflammations such as ulcerative colitis, Crohn's disease, pancreatitis, and gastritis, (2) gastrointestinal proliferative diseases such as gastrointestinal benign tumors, gastrointestinal polyp, familial polyposis syndrome, colon cancer, rectal cancer, and stomach cancer, (3) gastrointestinal ulcers. They are also preventives and/remedies for (1) angina pectoris or myocardial infarction or its after effect of disease (sequelae), (2) senile dementia, and (3) cerebral vascular dementia based on improving energy metabs. Thus, 2,4-dichloroiodobenzene was coupled with Et 2-isopropoxy-3-[3-(2-propynyloxy)phenyl]propanoate in the presence of (Ph3P)4Pd, CuI, and Et3N in DMF at room temperature for 2 days followed by hydrolysis with a mixture of 5 N aqueous NaOH and MeOH and acidification with 1 N aqueous HCl, 2-isopropoxy-3-[3-[3-(2,4-dichlorophenyl)-2-propynyl]oxyphenyl]propanoic acid (II). II showed EC50 of 0.008, 1.249, and 0.008 nM for increasing the transcription of human PPAR α, β, and γ, resp., in yeast transfected with GAL4-PPAR LBD chimera expression vector.

CLASSIFICATION CODE: 25-24
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
phenylpropionic acid prepn dual triple agonist PPAR; peroxisome proliferator activated receptor agonist phenylpropionic acid prepn; insulin resistance improver phenylpropionic acid prepn; hypolipidemic phenylpropionic acid prepn; osteoporosis treatment phenylpropionic acid prepn; antiinflammatory phenylpropionic acid prepn; immunomodulator anticancer phenylpropionic acid prepn; hyperlipidemia obesity diabetes prevention treatment

phenylpropionic acid prepn; diabetes complication prevention treatment phenylpropionic acid prepn; fragile X syndrome prevention treatment phenylpropionic acid prepn; digestive tract disease prevention treatment phenylpropionic acid prepn; indolylpropionic acid prepn dual triple agonist PPAR

REGISTRY NUMBER:

50-84-0 (2,4-Dichlorobenzoic acid)
59-31-4 (2-Hydroxyquinoline)
59-50-7 (4-Chloro-3-methylphenol)
74-88-4 (Methyl iodide)
75-03-6 (Iodoethane)
90-14-2 (1-Iodonaphthalene)
94-75-7 (2,4-Dichlorophenoxyacetic acid)
94-99-5 (2,4-Dichlorobenzyl chloride)
95-00-1 (2,4-Dichlorobenzylamine)
95-65-8 (3,4-Dimethylphenol)
95-87-4 (2,5-Dimethylphenol)
98-53-3 (4-tert-Butylcyclohexanone)
98-54-4 (4-tert-Butylphenol)
99-89-8 (4-Isopropylphenol)
102-47-6 (3,4-Dichlorobenzyl chloride)
103-71-9 (Phenyl isocyanate)
103-90-2 (4-Acetamidophenol)
104-12-1 (4-Chlorophenyl isocyanate)
104-86-9 (4-Chlorobenzylamine)
105-13-5 (4-Methoxybenzyl alcohol)
105-67-9 (2,4-Dimethylphenol)
106-41-2 (4-Bromophenol)
106-44-5 (4-Methylphenol)
106-48-9 (4-Chlorophenol)
106-89-8 (Epichlorohydrin)
106-93-4 (1,2-Dibromoethane)
106-96-7 (Propargyl bromide)
107-19-7 (Propargyl alcohol)
107-21-1 (Ethylene glycol)
107-30-2 (Chloromethyl methyl ether)
108-39-4 (3-Methylphenol)
108-43-0 (3-Chlorophenol)
108-59-8 (Dimethyl malonate)
120-83-2 (2,4-Dichlorophenol)
122-88-3 (4-Chlorophenoxyacetic acid)
123-07-9 (4-Ethylphenol)
123-31-9 (4-Hydroxyphenol)
124-63-0 (Methanesulfonyl chloride)
141-53-7 (Sodium formate)
149-73-5 (Trimethyl orthoformate)
328-73-4 (3,5-Bis(trifluoromethyl)iodobenzene)
329-01-1 (α,α,α-Trifluoro-m-tolyl isocyanate)
332-48-9 (1-(2-Bromoethoxy)-4-fluorobenzene)
348-60-7 (4-Chloro-3-fluorophenol)
348-62-9 (4-Chloro-2-fluorophenol)
349-95-1 (4-Trifluoromethylbenzyl alcohol)
352-34-1 (4-Fluoroiodobenzene)
367-12-4 (2-Fluorophenol)
395-44-8 (2-Trifluoromethylbenzyl bromide)
401-81-0 (3-Iodobenzotrifluoride)
402-23-3 (3-Trifluoromethylbenzyl bromide)
402-45-9 (4-Hydroxybenzotrifluoride)
402-49-3 (4-Trifluoromethylbenzyl bromide)

446-30-0 (4-Chloro-2-fluorobenzoic acid)
452-72-2 (4-Fluoro-2-methylphenol)
455-13-0 (4-Iodobenzotrifluoride)
455-19-6 (4-Trifluoromethylbenzaldehyde)
456-41-7 (3-Fluorobenzyl bromide)
459-46-1 (4-Fluorobenzyl bromide)
487-89-8 (Indole-3-carboxaldehyde)
495-76-1 (Piperonyl alcohol)
501-53-1 (Benzyl chloroformate)
524-38-9 (N-Hydroxyphthalimide)
527-60-6 (2,4,6-Trimethylphenol)
535-11-5 (Ethyl α-bromopropionate)
536-60-7 (4-Isopropylbenzyl alcohol)
583-78-8 (2,5-Dichlorophenol)
588-32-9 (3-Chlorophenoxyacetic acid)
588-63-6 ((3-Bromopropoxy)benzene)
589-10-6 ((2-Bromoethoxy)benzene)
589-18-4 (4-Methylbenzyl alcohol)
591-18-4 (3-Bromoiodobenzene)
611-17-6 (2-Chlorobenzyl bromide)
612-16-8 (2-Methoxybenzyl alcohol)
614-61-9 (2-Chlorophenoxyacetic acid)
615-37-2 (2-Iodotoluene)
620-17-7 (3-Ethylphenol)
621-42-1 (3-Acetamidophenol)
622-58-2 (p-Tolyl isocyanate)
622-95-7 (4-Chlorobenzyl bromide)
624-31-7 (4-Iodotoluene)
625-95-6 (3-Iodotoluene)
637-59-2 (3-Phenylpropyl bromide)
637-87-6 (4-Chloroiodobenzene)
696-62-8 (4-Methoxyiodobenzene)
702-23-8 (4-Methoxyphenethyl alcohol)
709-63-7 (4-Trifluoromethylacetophenone)
766-80-3 (3-Chlorobenzyl bromide)
766-85-8 (3-Methoxyiodobenzene)
767-00-0 (4-Hydroxybenzonitrile)
768-59-2 (4-Ethylbenzyl alcohol)
824-94-2 (4-Methoxybenzyl chloride)
836-42-0 (4-Benzyloxybenzyl chloride)
873-62-1 (3-Hydroxybenzonitrile)
873-75-6 (4-Bromobenzyl alcohol)
873-76-7 (4-Chlorobenzyl alcohol)
874-42-0 (2,4-Dichlorobenzaldehyde)
876-02-8 (4-Acetyl-2-methylphenol)
934-78-1 (2-(6-Methylpyridin-2-yl)ethanol)
939-26-4 (2-Bromomethylnaphthalene)
939-97-9 (4-tert-Butylbenzaldehyde)
940-64-7 (4-Methylphenoxyacetic acid)
1066-54-2 (Trimethylsilylacetylene)
1073-72-9 (4-(Methylthio)phenol)
1121-86-4 (3-Fluoroiodobenzene)
1122-41-4 (2,4-Dichlorothiophenol)
1131-60-8 (4-Cyclohexylphenol)
1138-56-3 (4-Butoxybenzenesulfonyl chloride)
1195-09-1 (2-Methoxy-5-methylphenol)
1195-45-5 (4-Fluorophenyl isocyanate)
1450-74-4 (2-Acetyl-4-chlorophenol)
1462-37-9 (Benzyl 2-bromoethyl ether)
1518-83-8 (4-Cyclopentylphenol)

1548-13-6 (α,α,α-Trifluoro-p-tolyl isocyanate)
1570-64-5 (4-Chloro-2-methylphenol)
1623-93-4 (4-Biphenylsulfonyl chloride)
1667-11-4 (4-Phenylbenzyl chloride)
1700-37-4 (3-Benzyloxybenzaldehyde)
1736-74-9 (4-Trifluoromethoxybenzyl alcohol)
1777-82-8 (2,4-Dichlorobenzyl alcohol)
1780-17-2 (2-Quinolinemethanol)
1798-04-5 (4-tert-Butylphenoxyacetic acid)
1805-32-9 (3,4-Dichlorobenzyl alcohol)
1875-88-3 (4-Chlorophenethyl alcohol)
2105-94-4 (4-Bromo-2-fluorophenol)
2212-08-0 ((Chloromethyl)di(isopropoxy)methylsilane)
2315-86-8 (3-Bromo-4-hydroxybenzonitrile)
2380-94-1 (4-Hydroxyindole)
2612-57-9 (2,4-Dichlorophenyl isocyanate)
2613-23-2 (3-Chloro-4-fluorophenol)
2713-33-9 (3,4-Difluorophenol)
2909-38-8 (3-Chlorophenyl isocyanate)
3209-13-0 (3-Methyl-5-methoxyphenol)
3300-51-4 (4-Trifluoromethylbenzylamine)
3320-83-0 (2-Chlorophenyl isocyanate)
3336-16-1 (3-Chloro-4-cyanophenol)
3437-95-4 (2-Iodothiophene)
4214-79-3 (2-Hydroxy-5-chloropyridine)
4394-85-8 (4-Formylmorpholine)
4397-53-9 (4-Benzyloxybenzaldehyde)
4421-08-3 (3-Methoxy-4-hydroxybenzonitrile)
4654-39-1 (4-Bromophenethyl alcohol)
4746-97-8 (1,4-Dioxaspiro[4.5]decan-8-one)
4856-97-7 (1H-Benzimidazole-2-methanol)
5061-21-2 (α-Bromo-γ-butyrolactone)
5182-44-5 (3-Chlorophenethyl alcohol)
5292-43-3 (tert-Butyl bromoacetate)
5306-98-9 (3-Chloro-6-methylphenol)
5416-93-3 (4-Methoxyphenyl isocyanate)
5470-11-1 (Hydroxylamine hydrochloride)
5541-67-3 (5-Methyl-8-quinolinol)
6214-44-4 (4-Ethoxybenzyl alcohol)
6214-45-5 (4-Butoxybenzyl alcohol)
6281-32-9 (4-Quinolinemethanol)
6346-05-0 (3-Benzyloxy-4-methoxybenzaldehyde)
6602-32-0 (2-Bromo-3-pyridinol)
6627-55-0 (2-Bromo-4-methylphenol)
6640-50-2 (1,2,3,4-Tetrahydro-8-quinolinol)
6850-57-3 (2-Methoxybenzylamine)
6953-22-6 (5-Benzyloxyindole-3-carboxaldehyde)
6966-10-5 (3,4-Dimethylbenzyl alcohol)
6971-51-3 (3-Methoxybenzyl alcohol)
7417-18-7 (2-Methoxyphenethyl alcohol)
7768-28-7 (2-Hydroxyphenethyl alcohol)
10031-82-0 (4-Ethoxybenzaldehyde)
10401-11-3 (3-Ethynylphenol)
13589-72-5 (4-Chloro-2-cyanophenol)
13669-51-7 (Quinolin-3-ylmethanol)
14191-95-8 (4-Cyanomethylphenol)
15852-73-0 (3-Bromobenzyl alcohol)
16271-33-3 (2,4-Dichlorobenzenesulfonyl chloride)
16315-59-6 (4-Dimethylaminophenyl isocyanate)

17201-43-3 (4-Cyanobenzyl bromide)
18162-48-6 (tert-Butyldimethylsilyl chloride)
18594-05-3 (4-Cyclohexylacetophenone)
18880-04-1 (3,4-Dichlorobenzyl bromide)
18908-07-1 (3-Methoxyphenyl isocyanate)
19692-45-6 (4-tert-Butylbenzyl chloride)
19853-09-9 (2-Phenylbenzyl bromide)
20443-98-5 (2,6-Dichlorobenzyl bromide)
20555-91-3 (3,4-Dichloroiodobenzene)
22445-41-6 (3,5-Dimethyliodobenzene)
23915-07-3 (2,4-Difluorobenzyl bromide)
24424-99-5 (Di-tert-butyl dicarbonate)
26177-44-6 (4-Bromobenzylamine hydrochloride)
28177-48-2 (2,6-Difluorophenol)
28188-41-2 (3-Cyanobenzyl bromide)
28229-69-8 (3-Bromophenethyl alcohol)
29898-32-6 (2,4-Dichloroiodobenzene)
30389-33-4 (5-Hydroxy-1,2,3,4-tetrahydro-2-quinolinone)
31680-08-7 (4-Methoxy-3-nitrobenzaldehyde)
32315-10-9 (Triphosgene)
32459-62-4 (4-Ethoxyphenyl isocyanate)
33252-63-0 (2-Hydroxy-5-trifluoromethylpyridine)
33445-07-7 (2-Isopropoxyacetic acid)
34145-05-6 (2,5-Dichlorobenzyl alcohol)
35037-73-1 (4-(Trifluoromethoxy)phenyl isocyanate)
37527-66-5 (3,4-Dimethoxyphenyl isocyanate)
37595-74-7 (N,N-Bis(trifluoromethanesulfonyl)aniline)
38493-59-3 (3-Bromo-4-methoxybenzyl alcohol)
39830-66-5 (Methyl 1H-indole-4-carboxylate)
39959-54-1 (3-Bromobenzylamine hydrochloride)
40465-45-0 (4-Cyanophenyl isocyanate)
40889-91-6 (2-Chloro-5-trifluoromethylphenol)
50823-90-0 (3-Trifluoromethoxybenzyl alcohol)
50824-05-0 (4-Trifluoromethoxybenzyl bromide)
57825-30-6 (4-Ethylbenzyl bromide)
59025-55-7 (2,4-Difluorophenyl isocyanate)
59377-19-4 (4-Phenoxyphenyl isocyanate)
60834-63-1 (4-Butylbenzyl alcohol)
65195-20-2 (2-Piperidinophenol)
69922-28-7 (3,4-(Methylenedioxy)phenyl isocyanate)
71672-75-8 (2-Ethoxybenzyl alcohol)
76283-09-5 (4-Bromo-2-fluorobenzyl bromide)
77771-02-9 (3-Bromo-4-fluorobenzaldehyde)
82380-18-5 (2-Fluoro-4-hydroxybenzonitrile)
82657-71-4 (4-Isopropoxybenzyl alcohol)
84370-87-6 (2,4-Dimethoxyphenyl isocyanate)
85118-05-4 (3,4-Difluorobenzyl alcohol)
90719-32-7 ((4S)-4-Benzyl-1,3-oxazolidin-2-one)
90925-43-2 (4-Propoxybenzyl alcohol)
114787-91-6 (4-Methoxy-3-methylbenzyl alcohol)
118712-60-0 ((S)-Glycidyl nosylate)
141483-15-0 (2-Fluoro-5-trifluoromethylphenol)
160233-27-2 (5-(3-Isoxazolyl)-2-thiophenesulfonyl chloride)
163839-73-4 (4-Trifluoromethylphenoxyacetic acid)
197239-49-9 (2-Fluoro-4-trifluoromethylbenzyl alcohol)
9004-10-8 (Insulin)

REGISTRY NUMBER: 478922-50-8; 478922-51-9; 478922-52-0; 478922-53-1; 478922-54-2; 478922-55-3; 478922-56-4; 478922-57-5; 478922-58-6; 478922-59-7; 478922-60-0; 478922-61-1;

478922-62-2; 478922-63-3; 478922-64-4; 478922-65-5;
478922-66-6; 478922-67-7; 478922-68-8; 478922-69-9;
478922-70-2; 478922-71-3; 478922-72-4; 478922-73-5;
478922-74-6; 478922-75-7; 478922-76-8; 478922-77-9;
478922-78-0; 478922-79-1; 478922-80-4; 478922-81-5;
478922-82-6; 478922-83-7; 478922-84-8; 478922-85-9;
478922-86-0; 478922-87-1; 478922-88-2; 478922-89-3;
478922-90-6; 478922-91-7; 478922-92-8; 478922-93-9;
478922-94-0; 478922-95-1; 478922-96-2; 478922-97-3;
478922-98-4; 478922-99-5; 478923-00-1; 478923-01-2;
478923-02-3; 478923-03-4; 478923-04-5; 478923-05-6;
478923-06-7; 478923-07-8; 478923-08-9; 478923-09-0;
478923-10-3; 478923-11-4; 478923-12-5; 478923-13-6;
478923-14-7; 478923-15-8; 478923-16-9; 478923-17-0;
478923-18-1; 478923-19-2; 478923-20-5; 478923-21-6;
478923-22-7; 478923-23-8; 478923-24-9; 478923-25-0;
478923-26-1; 478923-27-2; 478923-28-3; 478923-29-4;
478923-30-7; 478923-31-8; 478923-32-9; 478923-33-0;
478923-34-1; 478923-35-2; 478923-36-3; 478923-37-4;
478923-38-5; 478923-39-6; 478923-40-9; 478923-41-0;
478923-42-1; 478923-43-2; 478923-44-3; 478923-45-4;
478923-46-5; 478923-47-6; 478923-48-7; 478923-49-8;
478923-50-1; 478923-51-2; 478923-52-3; 478923-53-4;
478923-54-5; 478923-55-6; 478923-56-7; 478923-57-8;
478923-58-9; 478923-59-0; 478923-60-3; 478923-61-4;
478923-62-5; 478923-63-6; 478923-64-7; 478923-65-8;
478923-66-9; 478923-67-0; 478923-68-1; 478923-69-2;
478923-70-5; 478923-71-6; 478923-72-7; 478923-73-8;
478923-74-9; 478923-75-0; 478923-76-1; 478923-77-2;
478923-78-3; 478923-79-4; 478923-80-7; 478923-81-8;
478923-82-9; 478923-83-0; 478923-84-1; 478923-85-2;
478923-86-3; 478923-87-4; 478923-88-5; 478923-89-6;
478923-90-9; 478923-91-0; 478923-92-1; 478923-93-2;
478923-94-3; 478923-95-4; 478923-96-5; 478923-97-6;
478923-98-7; 478923-99-8; 478924-00-4; 478924-01-5;
478924-02-6; 478924-03-7; 478924-04-8; 478924-05-9;
478924-06-0; 478924-07-1; 478924-08-2; 478924-09-3;
478924-10-6; 478924-11-7; 478924-12-8; 478924-13-9;
478924-14-0; 478924-15-1; 478924-16-2; 478924-17-3;
478924-18-4; 478924-19-5; 478924-20-8; 478924-21-9;
478924-22-0; 478924-23-1; 478924-25-3; 478924-26-4;
478924-28-6; 478924-30-0; 478924-32-2; 478924-34-4;
478924-36-6; 478924-38-8; 478924-39-9; 478924-41-3;
478924-43-5; 478924-44-6; 478924-46-8; 478924-48-0;
478924-50-4; 478924-52-6; 478924-54-8; 478924-56-0;
478924-58-2; 478924-60-6; 478924-62-8; 478924-64-0;
478924-66-2; 478924-68-4; 478924-70-8; 478924-72-0;
478924-74-2; 478924-76-4; 478924-78-6; 478924-80-0;
478924-82-2; 478924-84-4; 478924-87-7; 478924-90-2;
478924-93-5; 478924-96-8; 478924-99-1; 478925-02-9;
478925-05-2; 478925-08-5; 478925-09-6; 478925-11-0;
478925-12-1; 478925-13-2; 478925-15-4; 478925-17-6;
478925-19-8; 478925-20-1; 478925-22-3; 478925-24-5;
478925-26-7; 478925-28-9; 478925-30-3; 478925-32-5;
478925-34-7; 478925-36-9; 478925-38-1; 478925-40-5;
478925-42-7; 478925-44-9; 478925-46-1; 478925-48-3;
478925-50-7; 478925-52-9; 478925-54-1; 478925-56-3;
478925-58-5; 478925-59-6; 478925-60-9; 478925-61-0;
478925-62-1; 478925-63-2; 478925-64-3; 478925-65-4;
478925-66-5; 478925-67-6

REGISTRY NUMBER: 478925-68-7; 478925-69-8; 478925-70-1; 478925-71-2;
478925-72-3; 478925-73-4; 478925-74-5; 478925-75-6;
478925-76-7; 478925-77-8; 478925-78-9; 478925-79-0;
478925-80-3; 478925-81-4; 478925-82-5; 478925-83-6;
478925-84-7; 478925-85-8; 478925-86-9; 478925-87-0;
478925-88-1; 478925-89-2; 478925-90-5; 478925-91-6;
478925-92-7; 478925-93-8; 478925-94-9; 478925-95-0;
478925-96-1; 478925-97-2; 478925-98-3;
478925-99-4; 478926-00-0; 478926-01-1; 478926-02-2;
478926-03-3; 478926-04-4; 478926-05-5; 478926-06-6;
478926-07-7; 478926-08-8; 478926-09-9; 478926-10-2;
478926-11-3; 478926-12-4; 478926-13-5; **478926-14-6**
; 478926-15-7; 478926-16-8; 478926-17-9; 478926-18-0;
478926-19-1; 478926-20-4; 478926-21-5; 478926-22-6;
478926-23-7; 478926-24-8; 478926-25-9; 478926-26-0;
478926-27-1; 478926-28-2; 478926-29-3; 478926-30-6;
478926-31-7; 478926-32-8; 478926-33-9; 478926-34-0;
478926-35-1; 478926-36-2; 478926-37-3; 478926-38-4;
478926-39-5; 478926-40-8; 478926-41-9;
478926-42-0; 478926-43-1; 478926-44-2; **478926-45-3**
; 478926-46-4; 478926-47-5; 478926-48-6; 478926-49-7;
478926-50-0; 478926-51-1; 478926-52-2; 478926-53-3;
478926-54-4; 478926-55-5; 478926-56-6; 478926-57-7;
478926-58-8; 478926-59-9; 478926-60-2; 478926-61-3;
478926-62-4; 478926-63-5; 478926-64-6; 478926-65-7;
478926-66-8; 478926-67-9; 478926-68-0; 478926-69-1;
478926-70-4; 478926-71-5; 478926-72-6; 478926-73-7;
478926-74-8; 478926-75-9; 478926-76-0; 478926-77-1;
478926-78-2; 478926-79-3; 478926-80-6; 478926-81-7;
478926-82-8; 478926-83-9; 478926-84-0; 478926-85-1;
478926-86-2; 478926-87-3; 478926-88-4; 478926-89-5;
478926-90-8; 478926-91-9; 478926-92-0; 478926-93-1;
478926-94-2; 478926-95-3; 478926-96-4; 478926-97-5;
478926-98-6; 478926-99-7; 478927-00-3; 478927-01-4;
478927-02-5; 478927-03-6; 478927-04-7; 478927-05-8;
478927-06-9; 478927-07-0; 478927-08-1; 478927-09-2;
478927-10-5; 478927-11-6; 478927-12-7; 478927-13-8;
478927-14-9; 478927-15-0; 478927-16-1; 478927-17-2;
478927-18-3; 478927-19-4; 478927-20-7; 478927-21-8;
478927-22-9; 478927-23-0; 478927-24-1; 478927-25-2;
478927-26-3; 478927-27-4; 478927-28-5; 478927-29-6;
478927-30-9; 478927-31-0; 478927-32-1; 478927-33-2;
478927-34-3; 478927-35-4; 478927-36-5; 478927-37-6;
478927-38-7; 478927-39-8; 478927-40-1; 478927-41-2;
478927-42-3; 478927-43-4; 478927-44-5; 478927-45-6;
478927-46-7; 478927-47-8; 478927-48-9; 478927-49-0;
478927-50-3; 478927-51-4; 478927-52-5; 478927-53-6;
478927-54-7; 478927-55-8; 478927-56-9; 478927-57-0;
478927-58-1; 478927-59-2; 478927-60-5; 478927-61-6;
478927-62-7; 478927-63-8; 478927-64-9; 478927-65-0;
478927-66-1; 478927-67-2; 478927-68-3; 478927-69-4;
478927-70-7; 478927-71-8; 478927-72-9; 478927-73-0;
478927-74-1; 478927-75-2; 478927-76-3; 478927-77-4;
478927-78-5; 478927-79-6; 478927-80-9; 478927-81-0;
478927-82-1; 478927-83-2; 478927-84-3; 478927-85-4;
478927-86-5; 478927-87-6; 478927-88-7; 478927-89-8;
478927-90-1; 478927-91-2; 478927-92-3; 478927-93-4;
478927-94-5; 478927-95-6; 478927-96-7; 478927-97-8;
478927-98-9; 478927-99-0; 478928-00-6; 478928-01-7;
478928-02-8; 478928-03-9; 478928-04-0; 478928-05-1;

REGISTRY NUMBER:

478928-06-2; 478928-08-4; 478928-10-8; 478928-11-9;
478928-12-0; 478928-13-1; 478928-14-2; 478928-15-3;
478928-16-4; 478928-17-5; 478928-18-6; 478928-19-7
478928-20-0; 478928-21-1; 478928-22-2; 478928-23-3;
478928-24-4; 478928-25-5; 478928-26-6; 478928-27-7;
478928-28-8; 478928-29-9; 478928-30-2; 478928-31-3;
478928-32-4; 478928-33-5; 478928-34-6; 478928-35-7;
478928-36-8; 478928-37-9; 478928-38-0; 478928-39-1;
478928-40-4; 478928-41-5; 478928-42-6; 478928-43-7;
478928-44-8; 478928-45-9; 478928-46-0; 478928-47-1;
478928-48-2; 478928-49-3; 478928-50-6; 478928-51-7;
478928-52-8; 478928-53-9; 478928-54-0; 478928-55-1;
478928-56-2; 478928-57-3; 478928-58-4; 478928-59-5;
478928-60-8; 478928-61-9; 478928-62-0; 478928-63-1;
478928-64-2; 478928-65-3; 478928-66-4; 478928-67-5;
478928-68-6; 478928-69-7; 478928-70-0; 478928-71-1;
478928-72-2; 478928-73-3; 478928-74-4; 478928-75-5;
478928-76-6; 478928-77-7; 478928-78-8; 478928-79-9;
478928-80-2; 478928-81-3; 478928-82-4; 478928-83-5;
478928-84-6; 478928-85-7; 478928-86-8; 478928-87-9;
478928-88-0; 478928-89-1; 478928-90-4; 478928-91-5;
478928-92-6; 478928-93-7; 478928-94-8; 478928-95-9;
478928-96-0; 478928-97-1; 478928-98-2; 478928-99-3;
478929-00-9; 478929-01-0; 478929-02-1; 478929-03-2;
478929-04-3; 478929-05-4; 478929-06-5; 478929-07-6;
478929-08-7; 478929-09-8; 478929-10-1; 478929-11-2;
478929-12-3; 478929-13-4; 478929-14-5; 478929-15-6;
478929-16-7; 478929-17-8; 478929-18-9; 478929-19-0;
478929-20-3; 478929-21-4; 478929-22-5; 92-91-1; 349-75-7;
405-09-4; 456-64-4; 1122-71-0; 2234-16-4; 3699-66-9;
6954-78-5; 7765-97-1; 13676-06-7; 17145-91-4; 19962-06-2;
20651-67-6; 34107-46-5; 40530-18-5; 40786-20-7;
42415-64-5; 54001-13-7; 56456-49-6; 67515-61-1;
71916-82-0; 81156-68-5; 86604-78-6; 87199-16-4;
90296-27-8; 97674-02-7; 103262-35-7; 109088-51-9;
115029-24-8; 123750-60-7; 125917-60-4; 142409-44-7;
158505-66-9; 169280-83-5; 173019-82-4; 181867-18-5;
215434-25-6; 219764-66-6; 230295-16-6; 239087-07-1;
243459-91-8; 334018-30-3; 478375-55-2; 478929-28-1;
478929-29-2; 478929-30-5; 478929-74-7; 478930-05-1;
478930-23-3; 120-36-5; 120-67-2; 1020-00-4; 3245-64-5;
5952-59-0; 6941-12-4; 6954-77-4; 22545-14-8; 58630-07-2;
73540-77-9; 81168-11-8; 81358-65-8; 103978-12-7;
125174-25-6; 153903-20-9; 156866-52-3; 160744-60-5;
170853-04-0; 171663-13-1; 201150-66-5; 251978-02-6;
325827-31-4; 334015-07-5; 334015-09-7; 334015-36-0;
334015-40-6; 334015-82-6; 334015-84-8; 334015-86-0;
334016-00-1; 334016-63-6; 334019-14-6; 343880-18-2;
467236-21-1; 467236-24-4; 470717-53-4; 478929-23-6;
478929-24-7; 478929-25-8; 478929-26-9; 478929-27-0;
478929-31-6; 478929-32-7; 478929-33-8; 478929-34-9;
478929-35-0; 478929-36-1; 478929-37-2; 478929-38-3;
478929-39-4; 478929-40-7; 478929-41-8; 478929-42-9;
478929-43-0; 478929-44-1; 478929-45-2; 478929-46-3;
478929-47-4; 478929-48-5; 478929-49-6; 478929-50-9;
478929-51-0; 478929-52-1; 478929-53-2; 478929-54-3;
478929-55-4; 478929-56-5; 478929-57-6; 478929-58-7;
478929-59-8; 478929-60-1; 478929-61-2; 478929-62-3;
478929-63-4; 478929-64-5; 478929-65-6; 478929-66-7;
478929-67-8; 478929-68-9; 478929-69-0; 478929-70-3;

```
                    478929-71-4; 478929-72-5; 478929-73-6; 478929-75-8;
                    478929-76-9; 478929-77-0; 478929-78-1; 478929-79-2;
                    478929-80-5; 478929-81-6; 478929-82-7; 478929-83-8;
                    478929-84-9; 478929-85-0; 478929-86-1; 478929-87-2;
                    478929-88-3
REGISTRY NUMBER:    478929-89-4; 478929-90-7; 478929-91-8; 478929-92-9;
                    478929-93-0; 478929-94-1; 478929-95-2; 478929-96-3;
                    478929-97-4; 478929-98-5; 478929-99-6; 478930-00-6;
                    478930-01-7; 478930-02-8; 478930-03-9; 478930-04-0;
                    478930-06-2; 478930-07-3; 478930-08-4; 478930-09-5;
                    478930-10-8; 478930-11-9; 478930-12-0; 478930-13-1;
                    478930-14-2; 478930-15-3; 478930-16-4; 478930-17-5;
                    478930-18-6; 478930-19-7; 478930-20-0; 478930-21-1;
                    478930-22-2; 478930-24-4; 478930-25-5; 478930-26-6;
                    478930-27-7; 478930-28-8; 478930-29-9; 478930-30-2;
                    478930-31-3; 478930-32-4; 478930-33-5; 478930-34-6;
                    478930-35-7; 478930-36-8; 478932-09-1


=> D IBIB ED ABS HITSTR L41 2; D IBIB ABS HITSTR L41 3-4

L41  ANSWER 2 OF 4  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2006:1147257  HCAPLUS  Full-text
DOCUMENT NUMBER:          145:471264
TITLE:                    Preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-
                          cyanophenoxy)-2-fluoropropoxy]phenyl]-2-
                          isopropoxypropionic acid calcium salt and its medical
                          application
INVENTOR(S):              Shinoda, Masanobu; Matsuura, Fumiyoshi; Murata, Kaoru;
                          Gotoda, Masaharu; Hayashi, Kenji; Sasho, Manabu;
                          Ozeki, Naoki; Inoue, Susumu; Nishiura, Katsutoshi;
                          Hisatake, Yoshihiko; Takigawa, Teiji; Miyazawa,
                          Mamoru; Negi, Shigeto; Inoue, Toru; Matsuyama, Keisuke
PATENT ASSIGNEE(S):       Eisai R & D Management Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 73pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2006115130         A1    20061102    WO 2006-JP308149         20060418
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     AU 2006240821         A1    20061102    AU 2006-240821           20060418
     US 2007117866         A1    20070524    US 2006-405619           20060418
     IN 2007DN06893        A     20070928    IN 2007-DN6893           20070906
PRIORITY APPLN. INFO.:                       US 2005-672512P      P   20050419
```

WO 2006-JP308149 W 20060418

OTHER SOURCE(S): MARPAT 145:471264
ED Entered STN: 02 Nov 2006
AB The title compound (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt was prepared in a multi-step synthesis. The title compound can be useful for the treatment of diabetes, syndrome X, hyperlipidemia, obesity, osteoporosis, etc. (no data). Formulations containing the title compound as an active ingredient were described.
IT 913722-78-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-
2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt)
RN 913722-78-8 HCAPLUS
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, calcium salt, trihydrate, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 913722-93-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-
2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt)
RN 913722-93-7 HCAPLUS
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, calcium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

IT **478926-45-3P 913722-90-4P 913722-91-5P**
913722-92-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-
fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt)

RN 478926-45-3 HCAPLUS
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913722-90-4 HCAPLUS
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913722-91-5 HCAPLUS
CN Benzenepropanoic acid, 3-[(2R)-3-(4-chloro-2-cyanophenoxy)-2-hydroxypropoxy]-α-(1-methylethoxy)-, ethyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913722-92-6 HCAPLUS
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, ethyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 3 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2007:135184 USPATFULL Full-text
TITLE: Calcium bis [(2S) - 3- [3-[(2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl]-2-isopropoxypropionate] and intermediate thereof
INVENTOR(S): Shinoda, Masanobu, Tsukuba-Shi, JAPAN
Matsuura, Fumiyoshi, Tsukuba-Shi, JAPAN
Murata, Kaoru, Tsukuba-Shi, JAPAN
Gotoda, Masaharu, Tsukuba-Shi, JAPAN
Hayashi, Kenji, Tsukuba-Shi, JAPAN
Sasho, Manabu, Tokyo, JAPAN
Ozeki, Naoki, Tsukuba-Shi, JAPAN
Inoue, Susumu, Hasaki-Machi, JAPAN
Nishiura, Katsutoshi, Hasaki-Machi, JAPAN
Hisatake, Yoshihiko, Hasaki-Machi, JAPAN
Takigawa, Teiji, Hasaki-Machi, JAPAN
Miyazawa, Mamoru, Hasaki-Machi, JAPAN
Negi, Shigeto, Hasaki-Machi, JAPAN
Matsuyama, Keisuke, Kobe-Shi, JAPAN
PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007117866	A1	20070524	
APPLICATION INFO.:	US 2006-405619	A1	20060418	(11)

NUMBER	DATE

PRIORITY INFORMATION: US 2005-672512P 20050419 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro- 2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. [Problem]There is need for (2S)-3-[3-[(2S)-3-(4-chloro-2- cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same. [Solution]Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2- isopropoxypropionic acid, solves the above problem. [Selected Drawing] None

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **913722-78-8P**
(drug candidate; preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-
2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt)
RN 913722-78-8 USPATFULL
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, calcium salt, trihydrate, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

●3/2 H2O

IT **913722-93-7P**
(drug candidate; preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-
2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt)
RN 913722-93-7 USPATFULL

CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, calcium salt, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

IT 478926-45-3P 913722-90-4P 913722-91-5P
913722-92-6P
(intermediate; preparation of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-
fluoropropoxy]phenyl]-2-isopropoxypropionic acid calcium salt)

RN 478926-45-3 USPATFULL

CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913722-90-4 USPATFULL

CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913722-91-5 USPATFULL

CN Benzenepropanoic acid, 3-[(2R)-3-(4-chloro-2-cyanophenoxy)-2-hydroxypropoxy]-α-(1-methylethoxy)-, ethyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913722-92-6 USPATFULL
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, ethyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 4 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2004:134097 USPATFULL Full-text
TITLE: Carboxylic acid derivative and salt thereof
INVENTOR(S): Matsuura, Fumiyoshi, Brookline, MA, UNITED STATES
Emori, Eita, Ibaraki, JAPAN
Shinoda, Masanobu, Ibaraki, JAPAN
Clark, Richard, Ibaraki, JAPAN
Sakai, Shunji, Ibaraki, JAPAN
Yoshitomi, Hideki, Ibaraki, JAPAN
Yamazaki, Kazuto, Ibaraki, JAPAN
Inoue, Takashi, Ibaraki, JAPAN
Miyashita, Safakazu, Ibaraki, JAPAN
Hihara, Taro, Ibaraki, JAPAN
Harada, Hitoshi, Ibaraki, JAPAN
Ohashi, Kaya, Tokyo, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004102634	A1	20040527	
APPLICATION INFO.:	US 2003-472543	A1	20031022	(10)
	WO 2002-JP3866		20020418	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-123346	20010420
	JP 2002-36274	20020214

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747

NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
LINE COUNT: 11273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. ##STR1##

Wherein R.sup.1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C.sub.1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C.sub.1-6 alkylene group, a C.sub.2-6 alkenylene group or a C.sub.2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C.sub.1-6 alkylene group, a C.sub.2-6 alkenylene group or a C.sub.2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C.sub.1-3 alkylene group, a C.sub.2-3 alkenylene group or a C.sub.2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; ##STR2##

represents a single bond etc.; X represents a single bond, oxygen atom, a group represented by --NR.sup.X1CQ.sup.1O-- (wherein Q.sup.1 represents an oxygen atom or sulfur atom; and R.sup.X1 represents a hydrogen atom, formyl group, or a C.sub.1-6 alkyl group etc., each of which may have one or more substituents), --OCQ.sup.1NR.sup.X1-- (wherein Q.sup.1 and R.sup.X1 are as defined above), --CQ.sup.1NR.sup.X1O-- (wherein Q.sup.1 and R.sup.X1 are as defined above), ONR.sup.X1CQ.sup.1-- (wherein Q.sup.1 and R.sup.X1 are as defined above), -Q.sup.2SO.sub.2-- (wherein Q.sup.2 is an oxygen atom or --NR.sup.X10-- (wherein R.sup.X10 represents a hydrogen atom, formyl group, or a C.sub.1-6 alkyl group etc., each of which may have one or more substituents)) or --SO.sub.2Q.sup.2- (wherein Q.sup.2 is as defined above),

(wherein, provided that R.sup.X2 and R.sup.X3, and/or R.sup.X4 and R.sup.X5 may together form a ring, Q.sup.3 and Q.sup.4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NR.sup.X10 (wherein NR.sup.X10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5- to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **478925-96-1P 478926-14-6P 478926-39-5P**
478926-45-3P
(preparation of phenylpropionic acid and indolylpropionic derivs. as dual or
triple agonists of peroxisome proliferator-activated receptors (PPAR) for preventives and/or remedies for diseases)

RN 478925-96-1 USPATFULL

CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-hydroxypropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 478926-14-6 USPATFULL
CN Benzenepropanoic acid, 3-[(2R)-3-(4-chloro-2-cyanophenoxy)-2-hydroxypropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 478926-39-5 USPATFULL
CN Benzenepropanoic acid, 3-[(2R)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 478926-45-3 USPATFULL
CN Benzenepropanoic acid, 3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]-α-(1-methylethoxy)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.